Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), completed enrollment for the 14-week Phase 2 INSPIRE trial of Zygel (Transdermal CBD Gel) in the treatment of behavioral symptoms of 22q11.2 deletion syndrome in children and adolescents. The company expects top-line data from this trial mid-year 2022.
“The completion of enrollment in our INSPIRE trial is an important step forward in advancing Zygel as a potential new treatment option for patients suffering from 22q,” stated Armando Anido, chairman and CEO of Zynerba. “Pending results from the INSPIRE trial and subsequent discussion with the FDA on the regulatory path forward, we plan to advance our clinical development program in 22q with Zygel. We are thankful for the combined efforts of our researchers, investigators and the patient and caregiver community.”
